Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

Yue Zhang†, Huizhu Qian†, Jing He* and Wen Gao*

Abstract

The tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) are newly discovered noncoding RNAs in recent years. They are derived from specific cleavage of mature and pre-tRNAs and expressed in various cancers. They enhance cell proliferation and metastasis or inhibit cancer progression. Many studies have investigated their roles in the diagnosis, progression, metastasis, and prognosis of various cancers, but the mechanisms through which they are involved in resistance to cancer treatment are unclear. This review outlines the classification of tRFs and tiRNAs and their mechanisms in cancer drug resistance, thus providing new ideas for cancer treatment.

Keywords: tRNA-derived fragments, tRNA halves, Cancer, Drug resistance, Biomarker

Background

Transfer RNAs (tRNAs) have long been regarded as classic noncoding RNAs and are involved in protein translation [1]. Recently, many researchers have discovered new noncoding RNAs that are derived from specific cleavage of pre- and mature tRNA. Noncoding RNAs derived from tRNA are grouped into two categories: tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) [1]. The tRFs originate from mature or pre-tRNAs, and they are approximately 14–30 nucleotides (nt) in length. tiRNAs are 29–50 nt in length and originate from specific cleavage of mature tRNA anticodon loop under stress [2, 3]. The tRFs are conservative and widespread in nature [4]. They were initially discovered as random tRNA degradation fragments and later found to be generated by conservative and specific tRNA cleavage [5]. The tRFs are associated with cancer, inherited metabolic diseases, viral infections, and neurodegenerative diseases [6]. Here, we introduce the classification of tRFs and tiRNAs, discuss their roles in cancers, summarize their mechanisms of drug resistance in cancer treatment, and describe techniques for studying tRFs and tiRNAs.

Classification of tRFs and tiRNAs and their roles in cancers

The tRFs include tRF-1, tRF-2, tRF-3, tRF-5, and i-tRF [5] (Fig. 1). The tRF-1 is produced by cleaving 3′ pre-tRNA by RNase Z or its cytoplasmic ribonuclease Z 2 (ELAC2) in the TψC loop [7]. tRF-1 has carcinogenic or anticancer effects in the occurrence and development of cancers [5]. tRF-2 is derived from the decomposition of anticodon loops of tRNAs under hypoxic condition [8]. Angiogenin and Dicer cleave the T-loop of 3′-ends of mature tRNA to produce tRF-3. tRF-3 includes tRF-3a and tRF-3b [7, 8]. Dicer cleaves the D-loop of tRNA to produce tRF-5. tRF-5 includes tRF-5a, tRF-5b, and tRF-5c [5]. The tRF-5 is mostly located in the nucleus, whereas tRF-3 and tRF-1 mainly occur in the cytoplasm [8]. The i-tRF spans the anticodon loop and is derived from mature tRNA [9]. The tiRNAs are produced by cleaving the anticodon loop of mature tRNA by angiogenin under stress conditions. There are two types of tiRNAs: 5′-tRNA half (tiRNA-5) and 3′-tRNA half (tiRNA-3) [10].
Nutritional deficiency, hypoxia, heat shock, and oxidative stress can stimulate angiogenin activity and increase tRNA cleavage [11].

The tRFs and tiRNAs regulate ribosome and protein biogenesis; DNA damage response; gene expression; RNA interference; immune mediation; and cell proliferation, apoptosis, and migration [4, 8, 57]. They are expressed and dysregulated in various cancers [58] (Table 1). The heterogeneity and stability of tRFs make it suitable biomarkers for cancer diagnosis and prognosis [19]. Acquired treatment resistance is the main dilemma of cancer treatment [59]. Many studies have systematically discussed the roles of tRFs and tiRNAs in the diagnosis, progression, metastasis, and prognosis of various cancers [1, 5], but few studies have investigated their roles in resistance to cancer treatment. Herein, we summarize their mechanisms in cancer drug resistance (Table 2).

Mechanisms of tRFs and tiRNAs in cancer drug resistance
Drug resistance occurs when the therapeutic efficacy of a drug decreases. Drug resistance is an obstacle to cancer treatment and patient survival. The tRFs and tiRNAs can replace eukaryotic translation initiation factor 4G (eIF4G) that binds to mRNA, thus inhibiting protein translation [41]. The downregulation of eIF4G increases doxorubicin sensitivity by inhibiting the expression of adenosine triphosphate-binding cassette (ABC) transporter in breast cancer cells [60]. ABC transporter can efflux anticancer drugs across cell membranes, which is associated with drug resistance of many solid tumors [13, 61]. The inhibition of eIF4F complex, including eIF4E, eIF4G, and eIF4A, enhances the sensitivity of various anticancer drugs, such as cisplatin sensitivity in non-small cell lung cancer (NSCLC) [62], trastuzumab and tamoxifen sensitivity in breast cancer [63, 64], and enzalutamide and bicalutamide sensitivity in castration-resistant prostate cancer (CRPA) [65]. In addition, tRFs and tiRNAs can promote the assembly of stress granules (SGs) under stress conditions [40]. SGs allow cells to recruit and protect mRNAs during stress [66]. SGs are related to drug resistance [67, 68]. The elimination of SG sequestration is associated with acquired drug resistance [69]. The assembly of SGs makes glioblastoma resistant to bortezomib, and thus, the drug is unable to inhibit angiogenesis [66].

Mechanisms of breast cancer resistance related to tRFs and tiRNAs
Breast cancer ranks second among the causes of female cancer-related deaths [70]. Chemotherapy resistance causes high mortality of patients with breast cancer [71]. The exact mechanisms of chemo-resistance have not yet been fully elucidated. Herein, we summarize the mechanisms by which tRFs play a role in resistance to breast cancer therapy.
| Cancer            | tRF/miR-1280     | tRNA-Leu and pre-miRNA | suppress colorectal cancer growth and metastasis | [29] |
|------------------|------------------|------------------------|-------------------------------------------------|------|
|                  | tRNA-Tyr-GTA     | tRNA-S                  | Targets of tRNA-Tyr-GTA are mainly enriched in the PPAR signaling pathway | [30] |
|                  | tRF-Gln-CTG      | tRF-5c                  | Negative regulation of c-Jun N-terminal kinase (JNK) cascade is enriched in tRF-Gln-CTG. Inhibition of JNK cascade can reduce the migration potential of colon cancer cells in vitro. | [30] |
|                  | tRF-Leu-TAG      | tRF-5a                  | Function of mesenchymal-to-epithelial transition is enriched in tRF-Leu-TAG. | [30] |
|                  | 5′-tRF-Lys-TTT, 5′-tRF-Val-CAC, 5′-tRF-Glu-TTC, 5′-tRF-Pro-GGG | tRF-5                  | Associate with chemotherapy treatment outcomes | [26] |
| prostate cancer  | tRF-1001         | tRF-1                   | TRF-1001 is required for cell proliferation. | [31] |
|                  | tRNA-Lys-CTT     | tRF                     | The ratio of tRFs derived from tRNA-Lys-CTT and tRNA-Phe-GAA is a good indicator of progression-free survival. | [32] |
|                  | tRNA-Phe-GAA     |                         |                                                 |      |
|                  | tRF-544          | tRF-S                   | High expression ratio of tRF-315/tRF-544 predicts poor PFS. | [32] |
|                  | tRF-315          | tRF-3                   |                                                 |      |
Resistance is common in triple-negative breast cancer (TNBC) [13]. Hypoxia is a characteristic of the tumor microenvironment and is related to tumor aggressiveness, metastatic potential, and chemoresistance [72]. Hypoxia can also induce tRFs. Hypoxia promotes chemoresistance to TNBC treatment in various ways. It can hinder drug penetration, affect cytotoxicity of drugs, induce breast cancer stem cell (CSC) phenotype, and regulate tumor immunity [72]. However, few studies have linked hypoxia-induced tRFs to drug resistance. Cui et al. studied the role of hypoxia-induced tRFs in doxorubicin resistance during TNBC treatment and found that tDR-0009 and tDR-7336 were significantly upregulated, while tDR-0124 and tDR-11,898 were downregulated. Gene ontology (GO) analysis indicates that tDR-0009 and tDR-7336 can maintain cell response to interleukin (IL)-6 [13]. IL-6 participates in multidrug resistance by activating the Janus kinase (JAK)/Signal transducer and activator of transcription 3 (STAT3), phosphoinositide 3-kinase (PI3K)/Protein Kinase B (Akt), and Ras-Mitogen-activated protein kinase (MAPK) pathways [50]. STAT3 mediates TNBC resistance through the NF-κB pathway, Bcl-2-associated x protein (Bax), and the TNFRSF1A gene [59, 73, 74]. In TNBC immunotherapy, STAT3 enhances PD-L1 expression, thus weakening the response to anti-PD-L1 therapy [75]. Furthermore, IL-6 can increase HIF-1α expression by activating STAT3.

| Cancer                      | tRFs and tiRNAs                                      | Type | Findings                                                                 | References |
|-----------------------------|------------------------------------------------------|------|--------------------------------------------------------------------------|------------|
| liver cancer                | SHOT-RNAAsp-GUC, SHOT-RNAHis-GUG, SHOT-RNAlys-CUU    | tRNA | SHOT-RNAs enhance cell proliferation.                                     | [20]       |
| cervical cancer             | tRF<sup>3</sup>                                      | tRF-3| Cleavage of tRNAs during stress                                          | [33]       |
| clear cell renal cell       | 5′-tRNA4-Val-AAC                                      | tRNA-S| inhibit the process of protein translation                               | [34]       |
| carcinoma                   | 5′-tRNA-Arg-CTT, 5′-tRNA-Glu-CTC, 5′-tRNA-Leu-CAG, 5′-tRNA-Lys-TTT | tRNA-S| Potential tumor suppressors                                              | [36]       |
| B cell lymphoma             | CU1276 (tRF-3018)                                    | tRF-3| CU1276 associates with argonaute proteins, represses endogenous RPA1, suppresses proliferation, and modulates molecular response to DNA damage. Loss of CU1276 expression may confer a growth advantage to malignant cells. | [37]       |
| ovarian cancer              | tRF<sup>Glu</sup>                                    | tRF-S| associate with Ago2 and downregulate target genes by transcript cleavage | [38]       |
| osteosarcoma                | tRF<sup>3</sup>-3357                                 | tRF-S| tRF-3357 promotes cell proliferation, migration, and invasion.          | [40]       |
| chronic lymphocytic leukemia| tRF<sup>1</sup>-tRNAs                                 | tRF-S| tRF-3 inhibits the proliferation of ovarian cancer cells.               | [39]       |
| head and neck squamous cell carcinoma | 5′-tRNA<sup>Ala</sup>, 5′-tRNA<sup>Cys</sup>, 5′-tRNA<sup>Tyr</sup> | tRNA-S| potential tumor suppressors                                              | [41]       |
| uveal melanoma              | tRF-22-BP4MYSZHZ, tRF-21-45DBNIB9B                    | i-RF | associated with metastasis and patient survival                          | [42]       |
| gastric cancer              | tRF-3019a                                            | tRF  | tRF-3019a overexpression enhances gastric cancer cell proliferation, migration, and invasion. | [43]       |
| testicular germ cell tumor  | tRF (20 nt)                                          | tRF  | Associated with cancer development and progression                       | [44]       |
HIF-1α mediates the expression of P-glycoprotein (P-gp) and Multidrug Resistance Protein 1 (MRP1) [50]. In conclusion, tDR-0009 and tDR-7336 may participate in the drug resistance of TNBC by regulating the activation of STAT3 phosphorylation [13]. Target genes of tDR-0124 are related to cell cycle regulation, while target genes of tDR-11,898 are involved in chemoresistance [13]. tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHOS3KSN are overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Huang et al. reported that tDR-5334, tDR-4733, and tDR-4733 were downregulated in nontriple-negative breast cancer patients compared to healthy people [16]. GO and KEGG pathway analyses indicate that the target genes of tDR-5334 are involved in the glycosylation process. Abnormal glycosylation is involved in the activation of oncogenic signaling pathways and induces cancer metastasis [16].

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Huang et al. reported that tDR-7816, tDR-5334, and tDR-4733 were downregulated in nontriple-negative breast cancer patients compared to healthy people [16]. GO and KEGG pathway analyses indicate that the target genes of tDR-5334 are involved in the glycosylation process. Abnormal glycosylation is involved in the activation of oncogenic signaling pathways and induces cancer metastasis [16].

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.

Sun et al. investigated tRFs related to trastuzumab resistance in human epidermal growth factor receptor-2 (HER2)-positive breast cancer [12]. tRF-30-JZOYJE22 RR33 and tRF-27-ZDXPHOS3KSN were overexpressed in trastuzumab-resistant patients. These two tRFs may lead to trastuzumab resistance by regulating the expression product of target genes or competing with mRNAs for binding to RNA-binding proteins [12]. They are intervention targets for predicting trastuzumab resistance in the treatment of breast cancer.
to-mesenchymal transition (EMT) partly explained the reason for trastuzumab resistance in HER2-positive breast cancer [78]. Glycosylation is a non-negligible multidrug resistance mechanism. The analysis of target genes of tDR-5334 revealed that STAT1 is the central protein in the protein-protein interaction (PPI) network [16]. STAT1 regulates ERα transcription and ERα signaling and is associated with tamoxifen resistance [51]. The analysis of target genes of tDR-4733 showed that tDR-4733 is involved in lipid metabolism and cell cycle regulation [16]. Changes in lipid metabolism mediate the development of acquired resistance to HER2 inhibitors through the PI3K/AKT/mTOR signaling [52]. The central protein cyclin B1 is a key part of cell cycle that causes cells to undergo mitosis [16]. Sabbaghi et al. reported that trastuzumab-entansine-induced cyclin B1 deficiency mediates drug resistance in HER2-positive breast cancer [79]. In addition, hypoxia can inhibit the expression of cyclin B1 in MCF-7 cells. Overexpression of cyclin B1 enhances paclitaxel sensitivity. Therefore, under hypoxic conditions, downregulated cyclin B1 can further promote paclitaxel resistance [80].

Mo et al. reported that the expression of 5′ fragment of tRNA-Val-CAC (5′-tRNAVal) was reduced in breast cancer [18]. The 5′-tRNAVal regulated cell proliferation, migration, and invasion in breast cancer. Frizzled homolog 3 (FZD3), β-catenin, c-myc, and cyclin D1 were downregulated, while Adenomatous Polyposis Coli (APC) was upregulated in cells overexpressing 5′-tRNAVal. The FZD3 protein is mapped to chromosome 8p21, a major component of the Wnt signaling pathway, which is involved in regulating early neural development [81]. The 5′-tRNAVal can directly bind to FZD3 and inhibit FZD3-mediated Wnt/β-catenin pathway [18], which is related to tamoxifen and doxorubicin resistance [82, 83]. In addition, the downregulation of FZD3 significantly reduces the expression of cyclin D1 and c-myc [18]. C-myc can confer chemoresistance in breast cancer cells [84, 85]. Seventy percent of patients with sporadic breast
cancer lose APC because of mutation or hypermethylation [86, 87]. The loss of APC results in resistance to doxorubicin and cisplatin by STAT3, EGFR, NOTCH, and Hedgehog signaling [88–90]. The STAT3 signaling pathway mainly plays a role in APC-mediated resistance to doxorubicin, but not to cisplatin [71]. To summarize, we speculate that 5′-tRNA Val plays a role in breast cancer chemoresistance through FZD3, β-catenin, c-myc, and APC.

In breast cancer, tRNAGlu, tRNAAsp, tRNAGly, and tRNATyr are exposed to stress and are enzymatically cleaved to produce tRFs [23]. The induction of these tRFs inhibits the stability of oncogenic transcripts by replacing 3′-UTR from the RNA-binding protein Y Box-Binding Protein 1 (YBX1), thereby inhibiting metastasis [23]. YBX1 is a versatile RNA-binding protein with a variety of interacting partners. Genetic inactivation of YBX1 leads to embryonic lethality [91]. YBX1 is overexpressed in multiple cancers [53] and enhances chemoresistance in melanoma [92], embryonal rhabdomyosarcoma [93], NSCLC [94], prostate cancer [95], gastric cancer [96], breast cancer [97], neuroblastoma [53], hepatocellular carcinoma [98], ovarian carcinoma [99], bladder cancer [100], diffuse large B-cell lymphoma [101], prostate cancer [102], chordomas [103], and esophageal squamous cell carcinoma (ESCC) [104]. YBX1 promotes cancer chemoresistance through upregulating ABC transporters related to multidrug resistance [53, 94, 97, 104, 105]. Overexpression of YBX1 confers resistance to mitoxantrone by cell adhesion mechanisms in diffuse large B-cell lymphoma [101]. In addition, YBX1 also transcriptionally activates the expression of drug resistance-related genes MVP/LRP, TOP2A, CD44, CD49f, BCL2, and MYC [106]. In summary, tRFs may increase chemosensitivity of various tumors by replacing 3′-UTR from YBX1.

In addition, Corce M et al. reported that ts-46 and ts-47 were upregulated by PIK3CA and KRAS mutations, respectively. These two mutations were involved in the resistance of breast cancer cells to lapatinib [26].

Chemoresistance causes high mortality of patients with breast cancer. The mechanisms by which tRFs induce chemoresistance in breast cancer can be applied to develop therapies to overcome drug resistance and prolong survival.

**Mechanisms of lung cancer resistance related to tRFs and tiRNAs**

Lung cancer has the highest mortality rate among all tumors. The 5-year survival rate is 19% [70]. Among all lung cancers, NSCLC accounts for more than 80% [107]. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) usually produce incomplete response within 9–12 months of treatment and then develop resistance. Shao et al. found that tRF-Leu-CAG was significantly upregulated in advanced NSCLC and promoted cell proliferation. Knockdown of tRF-Leu-CAG downregulated Aurora-A kinase (AURKA) in H1299 cells, indicating that tRF-Leu-CAG may be related to AURKA [27]. AURKA is a member of the Aurora kinase family of serine/threonine kinases and is involved in cell mitosis [108]. AURKA phosphorylates p53 at Ser315, resulting in its ubiquitination by Mdm2 and proteolysis [109]. In HCC827 cells, AURKA overexpression induced gefitinib resistance by downregulating the p53 signaling pathway [54]. The combination of EGFR-TKIs and AURKA inhibitors can suppress resistance [110]. Furthermore, in vitro data showed that AURKA overexpression was related to cisplatin resistance [55]. In addition to targeted therapy, the AURKA/NF-κB pathway is related to radio-resistance in docetaxel-resistant lung adenocarcinoma [111]. These data indicate that tRF-Leu-CAG may become a potential therapeutic target to reverse drug resistance in NSCLC. (Fig. 3).

Balatti et al. found that ts-101, ts-53, ts-46, and ts-47 were downregulated in lung cancer [25]. A functional enrichment study showed that ts-46 was associated with excessive activation of integrin-linked kinase (ILK) signaling, integrin signaling, platelet-derived growth factor (PDGF) signaling, sphingosine-1-phosphate (S1P) signaling, and mTOR signaling, while ts-101 was related to the overactivation of S1P signaling and glutamate receptor signaling. Both ts-46 and ts-101 were correlated with the inhibition of phosphatase and tensin homolog (PTEN) and ceramide signaling [25]. ILK is a serine/threonine protein phosphatase and related to tumor growth and metastasis [112]. RNA silencing of ILK enhances cisplatin sensitivity in lung adenocarcinoma by regulating the downstream genes p-GSK3β, p-AKT, AP-1, β-catenin, cyclin D1, and MMP-9 [113]. ILK participates in the resistance of lung cancer to gemcitabine through EMT and MRP1 [112]. Integrins are transmembrane proteins that can control aggressive behaviors of tumors [114]. Integrin stimulates ILK by binding to extracellular matrix components and further activates the protein kinase B/Akt. Akt activity determines resistance to cisplatin [113]. Integrin mediates EGFR-TKIs resistance through EMT, the KRAS-RalB-NF-κB pathway, and the Src/Akt pathway [115–118]. The integrin α(v)β3/ Src/Akt pathway confers NSCLC cells resistance to anti-IGF1R monoclonal antibody cixutumumab [119]. PDGF/PDGFR may be one of the mechanisms of excision repair cross-complementing 1 (ERCC1)-mediated cisplatin resistance [120]. PI3K/AKT/mTOR signaling promotes chemoresistance in lung cancer [121–123]. PTEN is a major negative regulator of the PI3K pathway [25]. PTEN inactivation is related to EGFR-TKIs resistance [124, 125]. Silencing of PTEN induces resistance to cisplatin and paclitaxel through the PI3K/Akt pathway in NSCLC [126–128]. ts-46 and ts-47 can counteract carcinogenic effects of KRAS mutations and simultaneously positively affect the p53 pathway [25].
The P53 pathway mediates cisplatin resistance in NSCLC [129, 130]. These data indicate that ts-101, ts-46, and ts-47 may be involved in drug resistance of lung cancer cells. (Fig. 3).

Mechanisms of pancreatic cancer resistance related to tRFs and tiRNAs
Pancreatic cancer (PC) has a high mortality rate, and the 5-year survival rate of patients with PC is only 8% [131]. Jin et al. reported that tRF-1391 and AS-tDR-000064 were associated with PC [28]. The KEGG pathway analysis showed that target genes of tRF-1391 were mainly concentrated in the PI3K/Akt pathway and 18 target genes of AS-tDR-000064 were related to resistance to EGFR-TKIs [28]. Metformin mediates PI3K/Akt/mTOR signaling, thereby enhancing the sensitivity of gemcitabine treatment in PC [132]. Furthermore, the PI3K/Akt signaling pathway is related to doxorubicin resistance in PC [56]. The roles of tRFs in drug resistance of PC need further research.

Mechanisms of colorectal cancer resistance related to tRFs and tiRNAs
Colorectal cancer (CRC) ranks third in morbidity and mortality among all tumors [70]. Chemoresistance leads to a low response rate to chemotherapy in advanced CRC [133]. Huang et al. reported that tRF/miR-1280 expression was reduced in CRC. tRF/miR-1280 was derived from tRNALeu and pre-miRNA. In addition, the miR-200b level decreased and Jagged-2 (JAG2), Gata1, Gata3, and zinc finger E-box binding homeobox 1 (Zeb1) levels increased in CRC [29]. JAG2 is a Notch ligand and is involved in tumor initiation and maintenance [134]. Gata factors are zinc finger DNA-binding proteins that control tissue development through the activation or repression of transcription [135]. tRF/miR-1280 binds to 3′-UTR of JAG2, thus inhibiting Notch/Gata and miR-200b signaling. The inactivation of Notch signal mediated by tRF/miR-1280 inhibits CSC phenotype through transcriptional repression of Gata1/3 and miR-200b signaling. The inactivation of Notch signal mediated by tRF/miR-1280 inhibits CSC phenotype through transcriptional repression of Gata1/3 and miR-200b signaling. The inactivation of Notch signal mediated by tRF/miR-1280 inhibits CSC phenotype through transcriptional repression of Gata1/3 and miR-200b signaling. The inactivation of Notch signal mediated by tRF/miR-1280 inhibits CSC phenotype through transcriptional repression of Gata1/3 and miR-200b signaling. The inactivation of Notch signal mediated by tRF/miR-1280 inhibits CSC phenotype through transcriptional repression of Gata1/3 and miR-200b signaling.

Fig. 3 tRF-Leu-CAG, ts-101, ts-46, and ts-47 are involved in drug resistance of lung cancer cells. Knockdown of tRF-Leu-CAG downregulates AURKA. AURKA overexpression induces gefitinib resistance by downregulating p53. The AURKA/NF-κB pathway is related to radio-resistance. ts-46 is associated with excessive activation of ILK, integrin, and mTOR signaling. Both ts-46 and ts-101 are correlated with the inhibition of PTEN signaling. RNA silencing of ILK enhances cisplatin sensitivity by regulating p-GSK3β, p-AKT, AP-1, β-catenin, cyclin D1, and MMP-9. Integrin activates Akt, which determines resistance to cisplatin. Integrin mediates EGFR-TKIs resistance through EMT, the KRAS-RalB-NF-κB pathway, and the Src/Akt pathway. Integrin/Src/Akt in NSCLC cells confers resistance to cixutumumab. PI3K/AKT/mTOR signaling promotes chemoresistance. ts-46 and ts-47 can affect the p53 pathway, which mediates cisplatin resistance in NSCLC.
Gata1 and Gata3 through the Notch pathway. Gata binds to miR-200b to inhibit transcription initiation. Inhibition of Gata1 increases miR-200b expression and reduces EMT [29]. EMT and miR-200b are involved in chemoresistance of CRC [140, 141]. Furthermore, Zeb1 and miR-200b regulate each other negatively. The genes ubiquitin-specific peptidase 17, chromodomain helicase DNA-binding protein 1-like, and double homeobox 4 are associated with DNA damage response. The inhibitory effect of Zeb1 on these three genes induces drug resistance [142]. In summary, tRF/miR-1280 may be involved in chemotherapy resistance of CRC. Drugs that targeting tRF/miR-1280 may reverse drug resistance in future treatment and prolong survival.

Wang et al. reported that tiRNA-Tyr-GTA and tRF-Gln-CTG were upregulated, while tRF-Leu-TAG was downregulated in CRC [30]. The tiRNA-Tyr-GTA, tRF-Gln-CTG, and tRF-Leu-TAG are tiRNA-5, TRF-5c, and tRF-5a with lengths of 30, 29, and 16 nt, respectively. The GO and KEGG pathway analysis indicated that the functions of tiRNA-Tyr-GTA targets are mainly negative regulation of epithelial cell apoptotic and peroxisome proliferator activated-receptor (PPAR) pathway [30]. PPAR is a ligand-activated transcription factor and is involved in regulating cancer progression [143]. The PPAR pathway is related to radiation resistance in CRC [144]. Inhibition of PPARα expression confers resistance to hydroxycamptothecin [145]. PPARδ confers resistance to PPARγ-induced apoptosis in CRC through mediation of survivin and caspase-3 [146]. In addition, tRF-Gln-CTG enhances the negative regulation of c-Jun N-terminal kinase (JNK) cascade and choline metabolism, while tRF-Leu-TAG enhances MET function [30]. Silencing of the JNK1 gene can dephosphorylate c-Jun and reduce transport of the G2 subfamily of ABC transporters (ABCG2). The JNK1/c-jun pathway is related to ABCG2-mediated multidrug resistance in CRC [147]. JNK activation can confer resistance to 5-FU in CRC patients with p53 mutation by inducing Bcl-2 phosphorylation [148]. Taken together, tiRNA-Tyr-GTA, tRF-Gln-CTG, and tRF-Leu-TAG may be involved in chemoresistance of CRC.

Mechanisms of ovarian cancer resistance related to tRFs and tiRNAs

Ovarian cancer (OC) is the fourth most common gynecological malignant tumor with high drug resistance [149]. High grade serous ovarian cancer (HGSOC) accounts for 75% of OC cases. Zhang et al. identified 27 differentially expressed tRFs, such as tRF-03357 and tRF-03358, from serum samples of patients with HGSOC and healthy controls. These 27 tRFs are involved in the MAPK, FoxO, and Wnt pathways [40]. Most patients with advanced OC develop treatment resistance [150]. MAPK is associated with acquired chemoresistance of OC [151]. The C-KIT/MAPK/MEK pathway establishes a link between platinum resistance and CSC phenotype in OC [152]. The Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis confers resistance to cisplatin [153]. The ERK/MAPK pathway promotes EMT phenotype, which is accompanied by increased cisplatin resistance [154]. The p38 MAPK activation upregulates p-glycoprotein expression, which enhances drug efflux, thereby inducing OC cell resistance to paclitaxel [155]. In addition, the activation of Wnt and its downstream molecules Wnt5a, β-catenin, c-Myc, and cyclin D1 upregulates the glycolysis level, thereby inducing cisplatin resistance in OC [156]. Fukumoto et al. showed that N6-methyladenosine of Frizzled family receptor 10 mRNA promoted resistance to poly (ADP)-ribose polymerase inhibitors (PARP) by upregulating the Wnt/β-catenin pathway in BRCA-mutated epithelial ovarian cancer (EOC) [157]. FoxO proteins have been reported to affect the effectiveness of anticancer drug treatment. Reduced FoxO1 expression is related to resistance to cisplatin [158]. To summarize, these differentially expressed tRFs affect the sensitivity of OC to chemotherapy, especially to cisplatin.

In addition, Zhou et al. reported that tRF5-Glu was expressed in OC. The tRF5-Glu binds to breast cancer antiestrogen resistance 3 (BCAR3) and downregulates its expression. BCAR3 and tRF5-Glu contribute to heterogeneity of OC [39]. Overexpression of BCAR induces antiestrogen resistance in breast cancer cells; however, it remains unclear whether BCAR has a similar effect in OC resistance [159, 160].

Mechanisms of chronic lymphocytic leukemia resistance related to tRFs and tiRNAs

Balatti et al. found that ts-101, ts-53, ts-46, and ts-47 were downregulated in chronic lymphocytic leukemia (CLL) [25]. As mentioned before, ts-46 is associated with integrin and ceramide signaling. ts-101 is associated with ceramide signaling inhibition [25]. The combination of fibronectin and αβ1 integrin induces fludarabine resistance in B-cell CLL by upregulating Bcl-xL [161]. Ceramide metabolism is related to fludarabine resistance in CLL [162]. In addition, the downregulation of ts-53 increases the Tcl1 expression level, leading to the progression of CLL [42]. However, the role of Tcl1 in chemoresistance of CLL remains unclear.

Techniques for studying tRFs and tiRNAs

In the process of studying tRF and tiRNA, it is quite important to differentiate between tRFs and randomly degraded fragments. By using specific amplification primers, tRFs and tiRNAs can be specifically detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of tRFs and tiRNAs can also be detected by northern blot [1]. Splinted ligation assay can measure the
levels of tRFs and tiRNAs. The assay depends on ligation between the 3′-end of tRF and the 5′-end of a ligation oligo, mediated through accurate annealing to a bridge oligo [31]. Microarray chips have been designed to study the expression of tRFs (shorter than 16 bp) in normal and tumor tissues [43]. Researchers have also established some databases to manage tRFs, such as trfdb (http://genome.bioch.virginia.edu/trfdb) [5], tRF2Cancer (http://rna.sysu.edu.cn/tRFfinder/) [58], YM500v3 database (http://ngs.ym.edu.tw/ym500/) [163], tRFexplorer (https://trfexplorer.cloud/) [164], and MINTbase v2.0 (http://cm.jefferson.edu/MINTbase/) [165]. Mitochondrial and Nuclear TRF mapping (MINTmap; https://github.com/TJU-CMC-Org/MINTmap/) is a software package for rapid and detailed identification of tRFs in short RNA-seq datasets. MINTmap can explicitly calculate and report raw and standardized abundances of discovered tRFs [1]. New technologies have led to breakthroughs in the exploration of tRFs and tiRNAs.

Conclusion
It is very common for tumors to acquire resistance to anticancer drugs. There is an urgent need to elucidate molecular mechanisms of cancer chemoresistance. This review outlines the classification of tRFs and tiRNAs, their roles in cancers, the mechanisms by which they play a role in cancer drug resistance, and the techniques for studying them. Their high equivalent and stability in body fluids, and differential expression between cancer patients and healthy controls open up broad prospects to develop screening, diagnostic, and prognostic biomarkers and targeted anticancer drugs that enhance the sensitivity of chemotherapeutic drugs. As the field is still in its infancy, it is a major challenge to fully understand the mechanism network of tRFs and tiRNAs in drug resistance. Overall, tRFs and tiRNAs give hope for cancer treatment, but further studies are required before clinical application. More work needs to be done to study broader and deeper mechanisms of tRFs and tiRNAs in drug resistance and the crosstalk between various signaling pathways.

Abbreviations
- tRFs: tRNA-derived Fragments; tiRNAs: tRNA halves; tRNA: transfer RNA; nt: Nucleotide; trRNA: 5′-tRNA half; tRNA-3: 3′-tRNA half; elf4G: Eukaryotic translation initiation factor 4G; ABC: Adenosine triphosphate-binding cassette; NSCLC: Non-small cell lung cancer; CRPA: Castration-resistant prostate cancer; SGs: Stress granules; TNBC: Triple-negative breast cancer; CSCs: Cancer stem cells; G0: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genome; IL: Interleukin; JAK: Janus kinase; STAT3: Signal transducer and activator of transcription 3; PI3K: Phosphoinositide-3-kinase; Akt: Protein Kinase B; MAPK: Mitogen-activated protein kinase; Bax: Bcl-2-associated x protein; mTOR: Mammalian target of rapamycin; P-gp: P-glycoprotein; MRP1: Multidrug Resistance Protein 1; Hh: Hedgehog; ER: Estrogen receptor; IGF2: Insulin-like growth factor 2; IGF1R: Insulin-like growth factor receptor 1; IR-A: Insulin receptor A; HER2: Human epidermal growth factor receptor-2; EMT: Epithelial-to-mesenchymal transition; FZD3: Frizzled homolog 3; APC: Adenomatous polyposis coli; TIC: Tumor initiating cell; YBX1: Y Box-Binding Protein 1; ESCC: Esophageal squamous cell carcinoma; EGFR: TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; ILK: Integulin-linked kinase; PDGF: Platelet-derived growth factor; S1P: Sphingosine-1-phosphate; PTEN: Phosphatase and tensin homolo; PC: Pancreatic cancer; CRC: Colorectal cancer; Zeb1: Zinc finger E-box binding homeobox 1; EMT: Epithelial-mesenchymal transition; PPAR: Peroxisome proliferator-activated receptors; iNKT: i-c-Jun N-terminal kinase; ABCC2: G2 subfamily of ABC transporters; OC: Ovarian cancer; HGSC: High-grade serous ovarian cancer; BCAR3: Breast Cancer Anti-Estrogen Resistance 3; CLL: Chronic lymphocytic leukemia

Acknowledgements
Not applicable.

Authors’ contributions
All authors contributed in the planning and writing of this review article. WG and JH are co-corresponding authors. YZ and HQ are co-first authors. The authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (81572262), the Jiangsu Province’s Key Provincial Talents Program (ZDRCA2016028), 333 high class Talented Man Project (BRA2016516) and the Natural Science Foundation of the Jiangsu Higher Education Institution of China (18KJB320006).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 4 August 2020 Accepted; 2 October 2020
Published online: 15 October 2020

References
1. Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31–7.
2. Sobala A, Hutvagner G. Transfer RNA-derived fragments: origins, processing, and functions. Wiley interdisciplinary reviews RNA. 2011;2(6):583–62.
3. Scares AR, Santos M. Discovery and function of transfer RNA-derived fragments and their role in disease. Wiley interdisciplinary reviews RNA. 2017;8(5).
4. Keam SP, Hutvagner G. tRNA-Derived Fragments (tRFs): Emerging New Roles for an Ancient RNA in the Regulation of Gene Expression. Life (Basel, Switzerland). 2015;5(4):1638–51.
5. Sun C, Fu Z, Wang S, Li J, Li Y, Zhang Y, et al. Roles of tRNA-derived fragments in human cancers. Cancer Lett. 2018;414:16–25.
6. Zhang S, Li H, Zheng L, Li H, Feng C, Zhang W. Identification of functional tRNA-derived fragments in senescence-accelerated mouse prone 8 brain. Aging. 2019;11(22):10485–98.
7. Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, Shao P, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3′ trails. PLoS One. 2012;7(9).
8. Kumar P, Kucu C, Dutta A. Biogenesis and function of transfer RNA-related fragments (tRFs). Trends Biochem Sci. 2016;41(8):679–89.
9. Telenis AG, Loher P, Honda S, Jing Y, Palazzo J, Kirino Y, et al. Dissecting tRNA-derived fragment complexities using personalized transcriptomes reveals novel fragment classes and unexpected dependencies. Oncotarget. 2015;6(28):24797–822.
10. Yamashita S, Ivanov P, Hu GF, Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J Cell Biol. 2009;185(1):35–42.
11. Thompson DM, Parker R. Stressing out over tRNA cleavage. Cell. 2009;138(2):215–9.
12. Sun C, Yang F, Zhang Y, Chu J, Wang J, Wang Y, et al. tRNA-derived fragments as novel predictive biomarkers for Trastuzumab-resistant breast cancer. Cell Physiol Biochem. 2018;49(2):419–31.

13. Cui Y, Huang Y, Wu X, Zheng M, Xia Y, Fu Z, et al. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. J Cell Physiol. 2019;234(6):8740–51.

14. Qin JJ, Yan Z, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38(1):195.

15. Falcioni M, Giangrossi M, Zabaleta ME, Wang J, Gambini V, Tilio M, et al. A novel 3′-tRNA (Glu)-derived fragment acts as a tumor suppressor in breast cancer by targeting nucleolin. FASEB J. 2019;33(12):13228–40.

16. Huang Y, Ge H, Zheng M, Cui Y, Fu Z, Wu X, et al. Serum tRNA-derived fragments (tRFs) as potential candidates for diagnosis of nontriple negative breast cancer. J Cell Physiol. 2020;235(3):2809–24.

17. Farina NH, Scallia S, Adams CE, Hong D, Fritz AJ, Messier TL, et al. Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer. J Cell Physiol. 2020;235(6):5318–27.

18. Mo D, Jiang P, Yang Y, Mao X, Tan X, Yang X, et al. A tRNA fragment, 5′-tRNA (Val), suppresses the Wnt/β-catenin signaling pathway by targeting FZD3 in breast cancer. Cancer Lett. 2019;457:60–70.

19. Wang X, Yang Y, Tan X, Mao X, Wei D, Yao Y, et al. Identification of tRNA-derived fragments expression profile in breast cancer tissues. Curr Genom. 2019;20(3):199–213.

20. Honda S, Loher P, Shigematsu M, Palazzo JP, Suzuki R, Imoto L, et al. Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci U S A. 2015;112(29):E3816–25.

21. Feng W, Li Y, Chu J, Li J, Zhang Y, Ding X, et al. Identification of tRNA-derived small RNA fragments as potential biomarkers for prediction of recurrence in triple-negative breast cancer. Cancer Med. 2018;7(10):5130–44.

22. Santarpia L, Bottai G, Kelly CM, Györgyi B, Székefi B, Puszta L. Deciphering and targeting oncogenic mutations and pathways in breast cancer. Oncologist. 2016;21(9):1063–78.

23. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast cancer progression via YB1 knockdown. Cell. 2015;161(4):790–802.

24. Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R. Mouse ES cells express a novel 3′-tRNA-Glu-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in BC cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1404–9.

25. Li Z, Ender C, Meister G, Moore PS, Chang Y, John B. Extensive terminal and asymmetric processing of small RNAs from tRNAs, snRNAs, snRNAs, and tRNAs. Nucleic Acids Res. 2012;40(14):6787–99.

26. Zhou X, Diebel J, Holy J, Shuldum A, Odean E, Hicks DA, et al. A tRNA fragment, tRFs-Glu, regulates BCA3 expression and proliferation in ovarian cancer cells. Oncotarget. 2017;8(56):9537–71.

27. Zhang M, Li F, Wang J, He W, Li Y, Li H, et al. tRNA-derived fragment tRF-03357 promotes cell proliferation, migration and invasion in high-grade serous ovarian cancer. OncoTargets Ther. 2019;12:6371–83.

28. Ivanov P, O’Day E, Emara MM, Wagner G, Lieberman J, Anderson P. G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced-tRNA fragments. Proc Natl Acad Sci U S A. 2014;111(51):18201–6.

29. Balatti V, Rizzotto L, Miller C, Palamaruch A, Fadda P, Pandolfo R, et al. TCL1 targeting miR-3676 is codelleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015;112(7):2169–74.

30. Pekarsky Y, Balatti V, Palamaruch A, Rizzotto L, Veneziano D, Nigita G, et al. Dysregulation of a family of short noncoding tRNAs, tRFs, in human cancer. Proc Natl Acad Sci U S A. 2016;113(18):5071–6.

31. Katsaraki K, Artemaki P, Papageorgiou SG, Pappa V, Scalias A, Kontos CK. Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay. Leuk Res. 2019;78:106234.

32. Kangour P, Katsaraki K, Papageorgiou SG, Pappa V, Scalias A, Kontos CK. Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. Hematol Oncol. 2019;37(4):498–504.

33. Veneziano D, Tomasello L, Balatti V, Palamaruch A, Rassenti LZ, Kipps TJ, et al. Dysregulation of different classes of tRNAs fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2019;116(48):24252–8.

34. Victoria Martinez B, Dhalbh JM, Nunez Lopez YG, Lampserska K, Golusinski P, Luzzewski L, et al. Circulating small non-coding RNA signature in head and neck squamous cell carcinoma. Oncotarget. 2015;6(22):19246–63.

35. Lodin E, Mage R, Shields CL, Lally SE, Sato T, Rigousoth I. IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. Pigment Cell Melanoma Res. 2020;33(1):52–62.

36. Zhang F, Shu J, Wu Z, Gao P, Zhang W, Qi B, et al. A 3′-tRNA-derived fragment enhances cell proliferation, migration and invasion in gastric cancer by targeting FBXO47. Arch Biochem Biophys. 2020;690:108467.

37. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295(1):110–23.

38. Hou Y, Li X, Li Q, Xu J, Yang H, Xue M, et al. STAT1 facilitates oestrogen receptor a transcription and stimulates breast cancer cell proliferation. J Cell Mol Med. 2018;22(12):6077–85.

39. Feng WW, Kurokawa M. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer. Cancer Drug Resistance (Alhambra, Calif). 2020;3(1). https://doi.org/10.20517/cdr.2019.100.93386.

40. Zhang H, Sun R, Chi Z, Li S, Hao L. Silencing of Y-box binding protein-1 by miR-181a enhances the sensitivity of pancreatic cancer cell to adriamycin. Eur Rev Med Pharmacol Sci. 2013;110(4):53–63.

41. Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao Z, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene. 2016;35(10):1302–13.
60. Pan X, Yang X, Zang J, Zhang S, Huang N, Guan X, et al. Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. Oncol Lett. 2017;13(6):4785–93.

61. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105–27.

62. Hao GJ, Hao HJ, Ding YH, Wen H, Li XF, Wang QR, et al. Suppression of eIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. FEBS Lett. 2017;591(4):363–45.

63. Zindy P, Bergé Y, Allal B, Firelone T, Pierredon S, Cammas A, et al. Formation of the eIF4f translation-initiation complex determines sensitivity to anticancer drugs targeting the eEF2R and HER2 receptors. Cancer Res. 2011;71(12):4068–73.

64. Fagan DH, Fettig LM, Avdulov S, Beckwith H, Peterson MS, Ho YY, et al. Acquired Tamoxifen resistance in MCF-7 breast cancer cells requires Hyperactivation of eIF4F-mediated translation. Hormones Cancer. 2017;8(4):219–29.

65. Jaiswal PK, Koul S, Shannugam PST, Koul HK. Eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) is upregulated during prostate cancer progression and modulates cell growth and metastasis. Sci Rep. 2018;8(1):7459.

66. Bittencourt LFF, Negreiros-Lima GL, Sousa LP, Silva AG, Ribeiro R, et al. G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentiating apoptosis. J Neuro-Oncol. 2019;144(3):463–73.

67. Christen KE, Davis RA, Kennedy D. Psammaplysin F increases the efficacy of sorafenib and sorafenib-like drugs in human prostate cancer cell lines. J Biol Chem. 2019;294(11):12043–55.

68. Christen KE, Davis RA, Kennedy D. Psammaplysin F increases the efficacy of sorafenib and sorafenib-like drugs in human prostate cancer cell lines. J Biol Chem. 2019;294(11):12043–55.

69. Yagüe E, Raguz S. Escape from stress granule sequestration: another way to drug resistance? Biochem Soc Trans. 2010;38(6):1537–42.

70. VanKloppenberg MK, Bedalov CO, Soto KF, Prosperi JR. APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer. 2015;15:457.

71. VanKloppenberg MK, Bedalov CO, Soto KF, Prosperi JR. APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer. 2015;15:457.

72. Nedeljković M, Damjanović A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge. Cells. 2019;8(9):957.

73. Kuo WY, Hwu L, Wu CY, Lee JS, Chang CW, Liu RS. STAT3/NF-kB-regulated Lentiviral TK/GCV suicide gene therapy for Cisplatin-resistant triple-negative breast cancer. Theranostics. 2017;7(3):647–63.

74. Egusquiguel E, Veh JE, Walker SR, Frank DA. The STAT3 Target Gene TNEFSF1A Mediates the NF-κB Pathway in Breast Cancer Cells. Neoplasia (New York, NY). 2019;21(12):1143–50.

75. Liu J, Yang Y, Wang H, Wang B, Zhao K, Jiang W, et al. Syntenin1-MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1. Breast Cancer Res Treat. 2018;171(1):345–57.

76. Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, et al. Defective Cyclin B1 induction in Trastuzumab-emtansine (T-DM1) treatment of breast cancer. Endocr Relat Cancer. 2015;22(3):R135–55.

77. Uchiimi T, Fotovati A, Sasaqu T, Shibahara K, Shimada T, Fukuda T, et al. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem. 2006;281(52):44040–9.

78. Schittek B, Psenner K, Sauer B, Meier F, Inther T, Garbe C. The increased expression of αtal in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 2007;120(10):2110–7.

79. Oda Y, Kohashi H, Yamamoto H, Tamiya S, Kohno K, Kuwano M, et al. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci. 2008;99(4):726–32.

80. Hyogotani A, Ito K, Yoshida K, Iizumi K, Kihara H, Kihara K, Amano J. Association of nuclear YB-1 localization with lung cancer-related protein and epithelial growth factor receptor expression in lung cancer. Clin Lung Cancer. 2012;13(5):375–84.

81. Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, et al. Expression of Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell formation and cell proliferation. J Cancer Res Clin Oncol. 2015;141(2):243–54.

82. Shihata T, Kato H, Murakami Y, Ueshino H, Watari K, Kawahara A, et al. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway. Oncotarget. 2017;8(9):1336–44.

83. Fujita T, Ito K, Iizumi K, Kimura M, Sano M, Nakagomi H, et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res. 2005;11(24 Pt 1):8837–44.

84. Chao HM, Huang HX, Chang PH, Tseng KC, Miyajima A, Chen E. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway. Oncotarget. 2017;8(2):2604–16.

85. Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CCHCR1 expression in ovarian cancer: their correlation with activated Akt, LRP1/MVP and P-glycoprotein Expression Cancer Sci. 2007;8(7):1020–6.

86. Yamashita T, Higashi M, Momose S, Morozumi M, Tamaru J. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. Int J Oncol. 2017;51(2):579–86.
101. Mao X, Wu Y, Wang Y, Zhu X, Yin H, He Y, et al. Y-box-binding protein 1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res. 2016;346(2):157–66.

102. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashigawa E, Uchiimi T, et al. Y-box binding protein 1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer. 2011;18(4):S50–57.

103. Liang C, Ma Y, Yong L, Yang C, Wang P, Liu X, et al. Y-box binding protein 1 promotes tumorigenesis and progression via the epidermal growth factor receptor/akt pathway in spinal chordoma. Cancer Sci. 2019;110(1):166–79.

104. Xu J, Hu Z. Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;79:717–22.

105. Chua PJ, Lim JP, Guo TT, Khanna P, Hu Q, Bay BH, et al. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells. Int J Oncol. 2018;53(6):2579–89.

106. Kuwano M, Shibata T, Watanuki K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110(5):1536–43.

107. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–39.

108. Nishimura Y, Endo T, Kano K, Naito K. Porcine Aurora a accelerates Cyclin B1 and Mos synthesis and promotes meiotic resumption of porcine oocytes. Anim Reprod Sci. 2009;113(1):1–8.

109. Shah KN, Bhatt R, Rotow J, Rohrborg J, Olivas V, Wang VE, et al. Aurora kinase a drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019;25(5):1111–18.

110. Liu JH, Hu L, Yang Z, Sun YU, Hoffman RM, Yi Z. Aurora-a/NF-kB signaling is associated with radio-resistance in Human Lung Adenocarcinoma. Anticancer Res. 2019;39(11):5991–1.

111. Jia Z. Role of integrin-linked kinase in drug resistance of breast cancer. Oncotargets and therapy. 2015;8:18227.

112. Feng X, Liu H, Zhang Z, Gu Y, Qiu H, He Z. Annexin A2 contributes to cisplatin resistance by activation of JNK/p38 pathway in non-small lung cancer cells. J Exp Clin Cancer Res. 2017;36(1):123.

113. Xing Y, Liu Y, Liu T, Meng Q, Hu L, Liu W, et al. TNNIP1 promotes the proliferation and cisplatin chemosensitivity of non-small cell lung cancer cells through MDM2/p53 pathway. Cell Commun Signaling. 2018;16(1):43.

114. Siegel RL, Miller KD, Jemal. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

115. Zhou HY, Yao XM, Chen XD, Tang JM, Qiao ZG, Wu XY. Mechanism of metformin enhancing the sensitization of human pancreatic cancer cells to gemcitabine by regulating the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(23):10283–9.

116. Kuclinaviciute E, Jonušiene V, Serauskienie A, Dabkeviciene D, Eidenaitė E, Laurinavičius A. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells. HCT116. J Cell Biochem. 2018;119(7):5913–20.

117. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011;121(4):1373–85.

118. Bartúnek P, Klášová J, Blendinger G, Dvorák M, Zeleník M. GATA-1 and c-myc crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myc promoter. Oncogene. 2003;22(13):1927–35.

119. Vaish V, Kim J, Shim M. Jagged-2 (JAG2) enhances tumorigenesis and chemoresistance of colorectal cancer cells. Oncotarget. 2017;8(12):35262–72.

120. Mirono G, Perra S, Shukla A, Marfe G. Involvement of Notch1 in resistance to Regorafenib in Colon Cancer cells. J Cell Physiol. 2016;231(5):1097–105.

121. Zhang F, Sun H, Zhang S, Yang X, Zhang G, Gu T. Overexpression of PBR3 inhibits self-renewal capability and chemoresistance of colorectal Cancer stem-like cells via inhibition of Notch-β-catenin signaling. Oncol Res. 2017;25(5):709–17.

122. Li DD, Zhao CH, Ding HW, Wu Q, Ren TS, Wang J, et al. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. Cell Prolif. 2018;51(5):e12480.

123. Kubiuliūtė R, Šulskytė L, Dainiūnaitė K, Daugelavicius R, Jarmalaite S. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line. Medicina (Kaunas, Lithuania). 2016;52(5):298–306.

124. Pérez-Ramírez C, Cahadas-Garre M, Molina M, Faus-Dáder MJ, Calleja-Hernández M. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16(16):1843–62.

125. Zhong J, Li L, Wang Z, Bai H, Gai F, Duan J, et al. Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). J Thorac Oncol. 2017;12(2):1766–78.

126. Lu C, Wang H, Chen S, Yang R, Li H, Zhang G. Bcl-2 inhibits growth in and induces cell death in S49 and H460 cells via miR-424-3p and targeting PTEN/PI3K/Akt pathway. J Cell Mol Med. 2018;22(4):2748–87.

127. De Marco C, Laudanna C, Rinaldi N, Oliveira MA, Ravo M, Weisz A, et al. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/Akt pathway in lung cancer. PLoS One. 2017;12(6):e0178865.

128. Sun H, Zhou X, Bao Y, Xiong G, Cui Y, Zhou H. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer. Open Biol. 2019;9(7):180227.

129. Lei L, Wang WX, Zhu YC, Li JL, Fang Y, Wang H, et al. Potential mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gemcitabine by regulating the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(23):10283–9.

130. Mirone G, Perra S, Shukla A, Marfe G. Involvement of Notch-1 in resistance to Regorafenib in Colon Cancer cells. J Cell Physiol. 2016;231(5):1097–105.

131. Zhang F, Sun H, Zhang S, Yang X, Zhang G, Gu T. Overexpression of PBR3 inhibits self-renewal capability and chemoresistance of colorectal Cancer stem-like cells via inhibition of Notch-β-catenin signaling. Oncol Res. 2017;25(5):709–17.

132. Li DD, Zhao CH, Ding HW, Wu Q, Ren TS, Wang J, et al. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. Cell Prolif. 2018;51(5):e12480.
activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene. 2012;31(8):1013–23.

147. Zhu MM, Tong JL, Xu Q, Nie F, Xu XT, Xiao SD, et al. Increased JNK signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One. 2012;7(8):e41763.

148. Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y, et al. JNK confers S-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep. 2014;4:4694.

149. Mitra T, Prasad P, Mukherjee P, Chaudhuri SR, Chatterjee U, Roy SS. Stemness and chemoresistance are imparted to the OC cells through TGFβ1 driven EMT. J Cell Biochem. 2018;119(7):5775–87.

150. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014;89(2):207–16.

151. Brasseur K, Gévy N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 2017;8(3):4008–42.

152. Muñoz-Galván S, Felipe-Abril B, García-Camacho M, Domínguez-Piñol J, Suarez-Martínez E, Verdugo-Siñanes EM, et al. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. J Exp Clin Cancer Res. 2019;38(1):234.

153. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, et al. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CYFTR1 axis. Ebiomedicine. 2019;90:200–304.

154. Zhou Y, Zhu Y, Fan X, Zhang C, Wang Y, Zhang L, et al. ND1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells. Oncotarget. 2017;8(20):33110–21.

155. Kang YS, Seok HJ, Jeong EJ, Kim Y, Yun SJ, Min JK, et al. DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Biochem Biophys Res Commun. 2016;478(1):403–9.

156. Gu ZW, He YF, Wang WJ, Tian Q, Di W. MRI-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway. J Zhejiang Univ Sci B. 2019;20(3):219–37.

157. Fukumoto T, Zhu H, Nacarelli T, Karakashhev S, Fakhutdinov N, Wu S, et al. N6-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79(11):2812–20.

158. Beretta GL, Corno C, Zaffaroni N, Pecore P. Role of FOXO Proteins in Cellular Response to Antitumor Agents. Cancers. 2019;11(1):90.

159. Cai D, Iyer A, Felekkis KN, Near RL, Luo Z, Chemoff J, et al. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PKC, and the cyclin D1 promoter. Cancer Res. 2003;63(20):6802–8.

160. Beretta GL, Corno C, Zaffaroni N, Pecore P. Role of FOXO Proteins in Cellular Response to Antitumor Agents. Cancers. 2019;11(1):90.

161. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marcos J, et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol. 2002;71(3):495–502.

162. Huang C, Tu Y, Freter CE. Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia. Oncotarget. 2018;9(69):33124–37.

163. Chung IF, Chang SJ, Chen CY, Liu SH, Li CY, Chan CH, et al. YM500v3: a database for small RNA sequencing in human cancer research. Nucleic Acids Res. 2017;45(D1):D925–d31.

164. La Ferlita A, Alaimo S, Veneziano D, Nigita G, Balatti V, Croce CM, et al. Identification of tRNA-derived ncRNAs in TGCA and NCI-60 panel cell lines and development of the public database tRFExplorer. Database. 2019;2019:baz115.

165. MINTBase v2.0: a comprehensive database for tRNA-derived fragments that includes nuclear and mitochondrial fragments from all the Cancer genome atlas projects. Nucleic Acids Res. 2018;46(D1):D152–d9.